drugset / Trial / NCT03091751
Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B
NaSingle-groupOpen-labelTreatment
Summary
The goal of this non-randomized, multi-center study in subjects with severe hereditary haemophilia B was to determine and compare the pharmacokinetic and safety profiles of BeneFIX in subjects having had 2 prior pharmacokinetic assessments with AlphaNine.
Timeline
- Start
- 2005-08
- Primary completion
- 2009-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BeneFIX | Protein / enzyme biologic | 65 iu/kg | — |
| Subject | BeneFIX | Protein / enzyme biologic | 75 iu/kg | — |